Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of high pressure-based instruments, consumables, and
related services for the global life sciences and other industries worldwide,
today announced its patented pressure cycling technology (“PCT”) platform was
prominently featured in 15 independent presentations at the annual conference
of the American Society for Mass Spectrometry (“ASMS”). The presentations at
the ASMS conference, held from June 1-6, 2019 in Atlanta, Georgia, spanned
PBI’s unique PCT platform’s wide ranging applications in scientific studies,
particularly in advancing knowledge and understanding in such areas as cancer
research, protein function, molecular biology, and biomarker discovery. “The
number of PCT-related presentations at the 2019 ASMS conference significantly
exceeded prior PBI records for a scientific meeting,” PBI’s Global Director of
Sales & Marketing Roxana McCloskey said in the news release. “We are
gratified that the use of our PCT platform continues to expand to new
investigators and laboratories worldwide, and that its use has shown great
promise in critical areas of human health, such as cancer. We believe the
presentations at this prestigious annual meeting clearly show the increasing
potential for the PCT platform in diagnostics and discovery, which we believe
could eventually lead to the routine use of the PCT platform in precision
medicine, a rapidly expanding market that is expected to reach $217 billion by
2028 (BIS Research, 2019).”
To view the full press release, visit http://ibn.fm/lAIfU
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired PreEMT technology from BaroFold,
Inc. to allow entry into the biologics contract research services sector, and
(2) the use of its recently-patented, scalable, high-efficiency, pressure-based
Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher
quality, homogenized, extended shelf-life or room temperature stable low-acid
liquid foods that cannot be effectively preserved using existing non-thermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
